Protecting the Liver and Kidneys from Bile Acid Damage
Hepatoprotective Mechanisms of Systemic Bile Acid Transporter Inhibitors
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11175410
This research explores how blocking certain bile acid transporters can protect the liver and kidneys in people with cholestatic liver disease, including Alagille Syndrome.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11175410 on ClinicalTrials.gov |
What this research studies
Our bodies have special transporters that manage bile acids, which are important for digestion but can harm the liver and kidneys if they build up. This project looks at a specific transporter called ASBT, found in the gut, kidneys, and liver, to understand its role in liver and kidney damage. We want to learn how medicines that block ASBT work to protect these organs. By using advanced techniques and special models, we aim to uncover the exact ways these inhibitors help, especially in conditions like Alagille Syndrome where bile flow is disrupted.
Who could benefit from this research
Good fit: Patients with cholestatic liver disease, such as Alagille Syndrome, who experience liver and kidney complications related to bile acid buildup, are the focus of this research.
Not a fit: Patients without cholestatic liver disease or related kidney injury would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to better treatments that protect the liver and kidneys for patients suffering from cholestatic liver diseases and related kidney injury.
How similar studies have performed: The applicant's previous work and strong preliminary data provide a solid foundation for this approach, suggesting potential for success.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAWSON, PAUL A — EMORY UNIVERSITY
- Study coordinator: DAWSON, PAUL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alagille Syndrome, Alagille-Watson Syndrome